-
公开(公告)号:US20120207797A1
公开(公告)日:2012-08-16
申请号:US13454235
申请日:2012-04-24
IPC分类号: A61K9/00 , A61P25/04 , A61P25/36 , A61K31/485
CPC分类号: A61K9/0002 , A61K9/2077 , A61K9/2081 , A61K9/2086 , A61K9/4808 , A61K9/5084 , A61K47/585
摘要: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.
摘要翻译: 通过在TPTA(Tamper Prone Therapeutic Agent)陷阱的剂型中或其剂型上存在来减少或延缓篡改剂型中所含药物的爆发释放的剂型。 如果剂型未被篡改,则TPTA捕获剂不会显着干扰药物从剂型中释放的速率。 然而,如果剂型已经被物理篡改,则TPTA捕获剂减少或阻止药物从剂型的爆发释放。
-
公开(公告)号:US08187636B2
公开(公告)日:2012-05-29
申请号:US11526502
申请日:2006-09-25
CPC分类号: A61K9/0002 , A61K9/2077 , A61K9/2081 , A61K9/2086 , A61K9/4808 , A61K9/5084 , A61K47/585
摘要: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.
摘要翻译: 通过在TPTA(Tamper Prone Therapeutic Agent)陷阱的剂型中或其剂型上存在来减少或延缓篡改剂型中所含药物的爆发释放的剂型。 如果剂型未被篡改,则TPTA捕获剂不会显着干扰药物从剂型中释放的速率。 然而,如果剂型已经被物理篡改,则TPTA捕获剂减少或阻止药物从剂型的爆发释放。
-
公开(公告)号:US20100099696A1
公开(公告)日:2010-04-22
申请号:US12587771
申请日:2009-10-13
申请人: Anthony Edward Soscia , Yingxu Peng , Yichun Sun , James R. Johnson , Atul J. Shukla , Wen Qu
发明人: Anthony Edward Soscia , Yingxu Peng , Yichun Sun , James R. Johnson , Atul J. Shukla , Wen Qu
IPC分类号: A61K47/32 , A61K47/26 , A61K31/485 , A61P25/36
CPC分类号: A61K31/44 , A61K9/1635 , A61K9/2027 , A61K9/2086 , A61K9/4866
摘要: Oral dosage form containing a therapeutically effective amount of a drug susceptible to abuse and an effective amount of an embolizing agent which causes the production of a solid or semi-solid embolus or blockage after tampering.
摘要翻译: 含有治疗有效量的易于滥用的药物和有效量的栓塞剂的口服剂型,其导致在篡改后产生固体或半固体栓塞或堵塞。
-
公开(公告)号:US20090239891A1
公开(公告)日:2009-09-24
申请号:US12087692
申请日:2007-02-28
申请人: Atul J. Shukla , James R. Johnson , Yichun Sun , Yingxu Peng , Shipeng Yu , Wen Qu , Timothy D. Mandrell
发明人: Atul J. Shukla , James R. Johnson , Yichun Sun , Yingxu Peng , Shipeng Yu , Wen Qu , Timothy D. Mandrell
IPC分类号: A61K31/4355 , A61K31/445
CPC分类号: A61K31/485 , A61K9/0019
摘要: Parenteral extravascular administration of a composition containing an analgesic medication of low water solubility that is dissolved, suspended, or emulsified in a solvent system results in the deposition of the analgesic medication at the site of administration and provides a controlled release of the analgesic medication from the site and a prolonged analgesia that may persist for several days following administration.
摘要翻译: 包含在溶剂体系中溶解,悬浮或乳化的含有低水溶性的镇痛药物的组合物的肠外外血管内给药导致镇痛药物在给药部位的沉积,并提供止痛药物的控制释放 部位和长时间的镇痛可能持续数日后给药。
-
公开(公告)号:US08349362B2
公开(公告)日:2013-01-08
申请号:US13454235
申请日:2012-04-24
CPC分类号: A61K9/0002 , A61K9/2077 , A61K9/2081 , A61K9/2086 , A61K9/4808 , A61K9/5084 , A61K47/585
摘要: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.
摘要翻译: 通过在TPTA(Tamper Prone Therapeutic Agent)陷阱的剂型中或其剂型上存在来减少或延缓篡改剂型中所含药物的爆发释放的剂型。 如果剂型未被篡改,则TPTA捕获剂不会显着干扰药物从剂型中释放的速率。 然而,如果剂型已经被物理篡改,则TPTA捕获剂减少或阻止药物从剂型的爆发释放。
-
公开(公告)号:US07560120B2
公开(公告)日:2009-07-14
申请号:US11194885
申请日:2005-08-01
申请人: Atul J. Shukla , James R. Johnson , Yichun Sun , Robert Cooper , Gregg Boring , Dan Scruggs
发明人: Atul J. Shukla , James R. Johnson , Yichun Sun , Robert Cooper , Gregg Boring , Dan Scruggs
IPC分类号: A61F2/02
CPC分类号: A61K9/0024 , A61K9/0012 , A61K9/0043 , A61K9/0048 , A61K31/00 , A61K31/65 , A61K47/14
摘要: A formulation containing one or more biologically active substances dissolved, dispersed, emulsified, or suspended within a vehicle of one or more citric acid esters and/or citric acid ethers. Methods for making and using are disclosed, as are kits for administration of the pharmaceutical formulation.
摘要翻译: 含有一种或多种在一种或多种柠檬酸酯和/或柠檬酸醚的载体中溶解,分散,乳化或悬浮的生物活性物质的制剂。 公开了制备和使用的方法,以及药物制剂的给药试剂盒。
-
公开(公告)号:US5169645A
公开(公告)日:1992-12-08
申请号:US429858
申请日:1989-10-31
IPC分类号: A61K9/16
CPC分类号: A61K9/1652 , A61K9/1617 , A61K9/1641
摘要: Directly compressible, wax-containing granules having improved flow properties are obtained when waxes are admixed in the melt with certain flow improving additives, followed by cooling and granulation of the admixture. In certain embodiments of the invention, only the wax itself melts in the melt combination of the wax(es) and additives(s), and in other cases both the wax(es) and the additives(s) will both melt. In either case, the melt combination of the wax(es) with the additive(s) yields, upon cooling and granulation, a wax-containing particulate drug diluent having improved and unexpected flow properties.
摘要翻译: 当将蜡与某些流动改进添加剂混合,然后将混合物冷却和造粒时,获得具有改善的流动性的直链可压缩的含蜡颗粒。 在本发明的某些实施方案中,只有蜡本身在蜡和添加剂的熔融组合中熔融,在其它情况下,蜡和添加剂都将熔化。 在任一种情况下,蜡(es)与添加剂的熔融组合在冷却和造粒时产生具有改进和意想不到的流动性质的含蜡颗粒药物稀释剂。
-
公开(公告)号:US20080075669A1
公开(公告)日:2008-03-27
申请号:US11526502
申请日:2006-09-25
IPC分类号: A61K9/44
CPC分类号: A61K9/0002 , A61K9/2077 , A61K9/2081 , A61K9/2086 , A61K9/4808 , A61K9/5084 , A61K47/585
摘要: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.
摘要翻译: 通过在TPTA(Tamper Prone Therapeutic Agent)陷阱的剂型中或其剂型上存在来减少或延缓篡改剂型中所含药物的爆发释放的剂型。 如果剂型未被篡改,则TPTA捕获剂不会显着干扰药物从剂型中释放的速率。 然而,如果剂型已经被物理篡改,则TPTA捕获剂减少或阻止药物从剂型的爆发释放。
-
公开(公告)号:US06432438B1
公开(公告)日:2002-08-13
申请号:US09605661
申请日:2000-06-28
申请人: Atul J. Shukla
发明人: Atul J. Shukla
IPC分类号: A61F1300
摘要: A biodegradable vehicle and filler (referred to in this invention as biodegradable vehicle), which can be mixed with one or more biologically active substances (BAS), or can be used as a biodegradable filler to fill in cavities or body tissues in animals, birds and humans. The consistency and rheology, hydrophilicity and hydrophobicity, and in vivo degradation rates of the biodegradable vehicle is controlled by modulating the molecular weight of polymers and copolymers, concentration of plasticizers, ratios of two or more plasticizer in the blends, types of polymers and copolymers, copolymer ratios, and ratios of blends of polymers with different molecular weights or different copolymers. The biodegradable vehicle is mixed with one or more BAS (which is separately stored away from the biodegradable vehicle in an appropriate container) just prior to use. Mixing of the BAS with the biodegradable vehicle can be accomplished by simply stirring the mixture with a stirring device, or by triturating the mixture or employing an ointment mill or a suitable device or apparatus or equipment that can be used for blending/mixing. Alternatively, a device, which resembles two syringes, attached together with a removable partition or a valve assembly can also be used to uniformly mix the BAS with the biodegradable vehicle. The mixing is performed in order to dissolve or uniformly suspend the BAS particles in the biodegradable vehicle. Modulating the polymer to plasticizer ratio, polymer molecular weight, copolymer ratio, and hydrophobicity and hydrophilicity of the plasticizer controls the release of the BAS from the biodegradable vehicle.
摘要翻译: 可生物降解的载体和填料(在本发明中称为可生物降解载体),其可与一种或多种生物活性物质(BAS)混合,或可用作可生物降解的填料以填充动物,鸟类的空腔或身体组织 和人类。 通过调节聚合物和共聚物的分子量,增塑剂的浓度,共混物中的两种或更多种增塑剂的比例,聚合物和共聚物的类型,可控制可生物降解载体的稠度和流变性,亲水性和疏水性以及体内降解速率, 共聚物比例以及具有不同分子量或不同共聚物的聚合物的共混物的比例。 可生物降解的车辆在使用之前与一个或多个BAS(在适当的容器中分开存储在可生物降解的车辆上)混合。 BAS与生物可降解载体的混合可以通过简单地用搅拌装置搅拌混合物,或通过研磨混合物或使用可用于混合/混合的软膏磨或合适的装置或设备来实现。 或者,也可以使用类似于两个注射器的装置,其与可拆卸的隔板或阀组件连接在一起,以将BAS与可生物降解的车辆均匀混合。 进行混合以便将BAS颗粒溶解或均匀地悬浮在可生物降解的载体中。 调节聚合物与增塑剂的比例,聚合物分子量,共聚物比例以及增塑剂的疏水性和亲水性控制了BAS从生物降解性载体的释放。
-
公开(公告)号:US06193991B1
公开(公告)日:2001-02-27
申请号:US09181515
申请日:1998-10-28
申请人: Atul J. Shukla
发明人: Atul J. Shukla
IPC分类号: A61F200
摘要: Biodegradable delivery systems of physiologically, pharmacologically and biologically active substance(s) (BAS) are provided. These systems are obtained by incorporating the BAS into a blend of biodegradable polymers and plasticizers using a novel solvent evaporation method. This method involves dissolving the biodegradable polymer or copolymer and a plasticizer into a volatile solvent. The BAS may then be added to this mixture. The volatile solvent is removed using vacuum or at an elevated temperature or using a combination of both vacuum and elevated temperature. The resultant mixture is a BAS-loaded formulation which when injected, implanted or applied in vivo in an animal or human, provides controlled release of the BAS over the desired period of time. Alternatively, a blank formulation may be first prepared by the aforementioned methodology without incorporating the BAS in the formulation. An appropriate quantity of BAS is then added to this formulation to yield a BAS-loaded formulation which may control the release of the BAS for the desired length of time.
摘要翻译: 提供了生理,药理和生物活性物质(BAS)的生物可降解递送系统。 这些系统通过使用新型溶剂蒸发法将BAS并入可生物降解聚合物和增塑剂的混合物中而获得。 该方法包括将可生物降解的聚合物或共聚物和增塑剂溶解在挥发性溶剂中。 然后可以将BAS加入到该混合物中。 使用真空或在升高的温度或使用真空和升高的温度的组合除去挥发性溶剂。 所得混合物是BAS-加载的制剂,其在动物或人体内注射,植入或施用时,在所需时间段内提供BAS的受控释放。 或者,可以首先通过上述方法制备空白制剂,而不在制剂中并入BAS。 然后将适量的BAS加到该配方中以产生BAS加载的配方,其可以控制BAS在所需时间长度上的释放。
-
-
-
-
-
-
-
-
-